Pharmaceutical Promotion to Physicians and First Amendment Rights

Abstract

Legal restrictions on off-label promotion of drugs are being challenged in the courts as a violation of First Amendment protection of “commercial speech.” The authors argue that public health concerns make pharmaceutical promotion different from other commercial speech and that more stringent regulation should be permitted.